A French Trial Suggests Hydroxychloroquine is Promising Yet Risky, but Wasn’t Randomized
chrismasterjohnphd.substack.com
A French hospital published results a few days ago of a non-randomized controlled trial testing hydroxychloroquine as a treatment for COVID-19. This looks like both good and bad news. The upside: 200 mg hydroychloroquine sulfate three times a day for ten days reduced the presence of the virus in nose and throat swabs to zero in 70% of the patients, whereas only 12.5% of the controls had swabs reduced to zero.
A French Trial Suggests Hydroxychloroquine is Promising Yet Risky, but Wasn’t Randomized
A French Trial Suggests Hydroxychloroquine is…
A French Trial Suggests Hydroxychloroquine is Promising Yet Risky, but Wasn’t Randomized
A French hospital published results a few days ago of a non-randomized controlled trial testing hydroxychloroquine as a treatment for COVID-19. This looks like both good and bad news. The upside: 200 mg hydroychloroquine sulfate three times a day for ten days reduced the presence of the virus in nose and throat swabs to zero in 70% of the patients, whereas only 12.5% of the controls had swabs reduced to zero.